enGene Therapeutics Inc.

US$1.75As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ENGNHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (30.88%)
Div yield —
ROE (60.50%)
Biotechnology
Beta (5Y) (0.24)
PE TTM —
TSR TTM (75.73%)
Mkt cap US$117.3M
ROIC (34.46%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.73
(1.00%)
(65.66%)
Hold 12|11|6|9|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.04
14.89%
17.53%
11.99%
2.44%
Revenue$M
11.28
11.22
11.85
12.38
11.03%
5.73%
8.85%
13.83%
Peers (US$117.3M)
Cap (US$)
PE
117.6M
—
Capital
TTM
5Y
10Y
Leveragex
1.167
1.138
0.738
EBIT/Intx
1.003
0.314
0.330
Own earn%
47.45
(37.66)
(41.23)
Sh yield%
35.88
43.29
40.92
Owners
Insiders/Inst%
2.04
20.58
Short interest%
3.45
SBC / revenue%
1.71
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
11–16
$1 testx
0.4
Incr. ROIC%
−1